Latest news with #smokerslung
Reuters
3 days ago
- Business
- Reuters
Regeneron shares slide on mixed trial data on smoker's lung drug
May 30 (Reuters) - Regeneron (REGN.O), opens new tab shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. Regeneron and partner Sanofi ( opens new tab were studying the potential blockbuster drug, itepekimab, as a treatment for chronic obstructive pulmonary disease (COPD) in adult former smokers. The condition has limited treatment options and the drug was expected to target a broader patient population compared to Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition. But after Friday's data, Barclays analyst Emily Field said Dupixent is likely to remain the first choice for doctors. GSK's (GSK.L), opens new tab Nucala, approved recently for COPD, is also a blockbuster drug. Nearly 16 million U.S. adults suffer from COPD, according to government data. Regeneron's shares, which have already fallen 15% this year, were trading at $530 in premarket trading. The company has a market capitalization of $65.36 billion. The company's itepekimab showed a significant reduction in exacerbations or flare-ups in the condition by 27% compared to placebo at 52 weeks in a 1,127-patient study. But the second study - which had enrolled fewer former smokers compared to the first - did not meet its goal although a benefit was seen earlier in the trial. The experimental drug, which is being jointly developed by Regeneron and Sanofi, binds to and inhibits interleukin-33, a type of protein that causes inflammation in COPD. COPD is a common lung disease causing restricted airflow and breathing problems. It typically affects smokers, but can also be caused by pollutants. Sanofi and Regeneron are assessing the data and will discuss with regulatory authorities to evaluate their next steps, the companies said. Regeneron's price to earnings ratio, a common benchmark for valuing stocks, was 16.15, compared with 13.62 for Gilead (GILD.O), opens new tab and 7.29 for Bristol Myers Squibb (BMY.N), opens new tab.
Yahoo
23-05-2025
- Business
- Yahoo
GSK plc (GSK)'s Asthma Drug Gets FDA Nod to Treat ‘Smoker's Lung'
The U.S. Food and Drug Administration has approved GSK plc (NYSE:GSK)'s asthma medication, Nucala, for expanded use in treating a form of chronic obstructive pulmonary disease (COPD), often referred to as 'smoker's lung,' the company announced Thursday. This decision allows Nucala to be used as an add-on therapy for patients with a specific type of COPD. Nucala is a monoclonal antibody that targets interleukin-5, a protein involved in regulating eosinophils—white blood cells that can cause lung inflammation when present in excess. Though the FDA had originally aimed to make a decision by May 7, the approval came two weeks later, continuing a trend of missed deadlines following recent staffing cuts and restructuring within federal health agencies under Secretary of Health and Human Services Robert F. Kennedy Jr. The green light was supported by results from a late-stage clinical trial showing that patients taking Nucala along with standard inhaled therapy experienced 21% fewer disease flare-ups over a 104-week period compared to those given a placebo. In its press release, GSK plc (NYSE:GSK) highlighted that hospitalizations related to COPD are a growing burden on the healthcare system and could soon become the leading cause of medical admissions. Emergency room visits and inpatient treatments already represent a major share of the approximately $7 billion in annual COPD-related healthcare costs in the US. GSK has surged by nearly 15% in 2025 so far. While we acknowledge the potential of GSK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GSK and that has 100x upside potential, check out our report about this cheapest AI stock. READ MORE: and Disclosure. None.
